Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.54 |
| ▸ | PDE4A | P27815 | 12/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29044734 | 0.86 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL28163432 | 0.86 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL2961023 | 0.86 | PDE4B (0.57) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL7475124 | 0.86 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL18971899 | 0.86 | PDE4B (0.57) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL5038747 | 0.83 | PDE4B (0.55) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL5038816 | 0.83 | PDE4B (0.55) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL1157286 | 0.82 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL7421380 | 0.82 | PDE4B (0.51) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Hydrochloric Acid SCHEMBL31345245 | 0.81 | PDE4B (0.55) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750009-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20060116373-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
| WO-1993015044-A1 | N-BENZYLOXAMIC ACID, OXAMATE, AND OXAMIDE DERIVATIVES AND THEIR USE AS TNF AND PDE IV INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116373-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | PDE4B 1709/4885PDE4D 2722/4885PDE4A 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.